Examination of product candidates for the prevention of HPV-associated diseases Martinsried/Munich, May 31, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) and The Johns Hopkins …
MediGene Signs Veregen® Commercialization Agreement with SynCore Bio in Taiwan
Martinsried/Munich, May 18, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) has signed an exclusive license and supply agreement with SynCore Bio, a subsidiary of the Sinphar Group, …
MediGene Reports Profit for the First Three Months of 2011
- Increase in revenue (from continued and discontinued operations) to EUR 27.9 million (Q1 2010: EUR 12.0 million) - Positive EBITDA result of EUR 19.2 million (Q1 2010: EUR -2.4 million) - Net profit …
MediGene and Will-Pharma Sign Agreement for the Commercialization of Veregen® in Benelux
Martinsried/Munich, March 10, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) has signed an exclusive license and supply agreement with Will-Pharma for the commercialization and …
MediGene Adds Romania and Bulgaria to Existing Partnership Agreement with Meditrina for the Commercialization of Veregen®
Martinsried/Munich, January 25, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) announced today that its existing partnership with Meditrina Pharmaceuticals Ltd., Greece, for the …